Talking about the darling of the preeclampsia screening community-placental growth factor (1) | Discovery of PLGF
Angiogenesis is a complex process. This process is stimulated by a variety of angiogenic growth factors, such as platelet-derived endothelial cell growth factor, transforming growth factors alpha and beta, and vascular permeability factor (VPF). VPF is also called vascular endothelial growth factor (VEGF). Placenta growth factor (PLGF) is a member of the VEGF family and is mainly expressed in placental trophoblast cells. PLGF is involved in uterine spiral artery recasting and placental angiogenesis. Studies have shown that in pregnant women with preeclampsia, the concentration of PLGF is significantly lower than that of normal pregnant women. Detecting the blood PLGF level of pregnant women is very meaningful for predicting, identifying and monitoring the treatment of preeclampsia. In this issue, let’s talk about the relationship between PLGF and PLGF and preeclampsia (PE).
Case Sharing | Pre-eclampsia-like symptoms in pregnant women with new crowns need to be carefully identified
Due to the physiological changes of the immune system and the heart and lung systems, pregnant women are more likely to develop serious diseases after being infected with respiratory viruses such as COVID-19. The incidence of preeclampsia is increased in pregnant women infected with COVID-19. There may be features of preeclampsia in some preeclampsia with a severe course of COVID-19, which should be distinguished from true preeclampsia through more detailed examination. This article reports the first case of maternal death in Iran due to COVID-19 during childbirth due to preeclampsia.
Sharing of cutting-edge applications of PLGF | PLGF and gestational diabetes
Gestational diabetes mellitus (GDM) is one of the most common pregnancy complications. Most of the glucose metabolism of GDM patients can return to normal after delivery, but the probability of developing type II diabetes will increase in the future. The clinical manifestations of pregnant women with gestational diabetes are complicated, and both the mother and the fetus are at risk, and clinical attention should be paid to it. At present, in order to diagnose gestational diabetes, pregnant women between 24-28 weeks of gestation generally should undergo a sugar screening test. However, with the progress of research, it is found that placental growth factor (PLGF) may be able to indicate the occurrence of gestational diabetes.
Academic Sharing | The Impact of Preeclampsia on the Long-term Diseases of Maternal and Offspring
The pregnancy process can be regarded as a "stress test". How to deal with the physiological changes during pregnancy and how to deal with it will have a certain impact on the development of future health complications. Studies have found that if a pregnant woman develops gestational diabetes during pregnancy, the probability of her and her offspring suffering from type 2 diabetes will be much higher than that of normal pregnant women and offspring. Therefore, it is recommended to conduct routine screening for gestational diabetes during pregnancy in order to check Provide good care for the patient's pregnancy and the healthy development of her and her offspring. Placental ischemic disease affects the outcome of pregnancy, and there are many long-term effects on the mother and her offspring. Preeclampsia is a kind of placental ischemic disease. In this issue, let’s talk about the impact of preeclampsia during pregnancy on the long-term disease of the mother and offspring.
Academic Sharing | The impact of fetal growth restriction on long-term diseases of the mother and offspring
Fetal growth restriction (FGR), also known as intrauterine growth restriction (IUGR), is a common pregnancy complication associated with a variety of adverse perinatal outcomes. Globally, FGR affects nearly 10% of pregnancies. The incidence rate in my country is 6.39%, which is the second leading cause of perinatal death. In this issue, let's talk about the impact of fetal growth restriction on the long-term disease of the mother and offspring.
Academic Sharing | The Impact of Placental Abruption on Long-term Diseases of Maternal and Offspring
Placental abruption (Placental abruption) occurs after 20 weeks of pregnancy or during childbirth. The placenta in the normal position is partially or completely peeled off from the uterine wall before the fetus is delivered. Placental abruption affects 0.4-1% of pregnancies and is one of the main causes of perinatal morbidity and death in pregnant women. A large number of studies have shown that placental abruption not only threatens the life of the mother and fetus in the perinatal period, but also has many harms to their long-term diseases. In this issue, let's talk about the impact of placental abruption on the long-term disease of the mother and offspring.
Academic Sharing | Uterine Arterial Doppler Ultrasound in the Second Trimester and Adverse Pregnancy Outcomes Original Orient Biomedicine Department Orden Medical July 23
The second trimester generally refers to the period from 14 weeks to 27 weekends of pregnancy. In the second trimester, because the placenta has formed, the fetus has entered a relatively safe stage. However, the abnormality of some test indicators in the second trimester is often a predictor of adverse pregnancy outcomes. In this issue, let’s talk about the relationship between uterine artery Doppler ultrasound in the second trimester (including uterine artery resistance index RI, uterine artery pulsatility index PI, uterine artery early diastolic notch) and adverse pregnancy outcomes.
Literature Interpretation | How to effectively screen for PE and FGR in the first trimester
Preeclampsia (PE) is not only one of the main causes of maternal and fetal death, but also other adverse pregnancy outcomes, such as fetal growth restriction (FGR). At present, PE and FGR are still clinical problems that plague obstetrics. "Comparison of preeclampsia and fetal growth restriction screenings at first trimester in a high-risk population" compares combined maternal risk factors, mean arterial pressure (MAP), uterine artery pulsatility index (UTPI), placental growth factor (PLGF), pregnancy-related The sensitivity and specificity of plasma protein (PAPP-A) to PE and FGR screening, and it was found that combining these indicators can better identify pregnant women at high risk of PE and FGR in high-risk populations. This article is a specific interpretation of this document
Literature Interpretation | PLGF test for pregnant women with suspected preeclampsia can independently predict delivery time
Studies have shown that placental growth factor (PLGF) can be used to predict preeclampsia (PE). However, the clinical management of pregnant women at high risk of PE, especially premature delivery caused by PE, is still a major clinical problem.《Placental growth factor predicts time to delivery in women with signs or symptoms of early preterm preeclampsia: a prospective multicenter study》It mainly evaluated the relationship between PLGF detection and delivery time in pregnant women with suspected preeclampsia, and proved that low concentrations of PLGF can independently and effectively predict preterm delivery. This article is a specific interpretation of this document.
Literature interpretation | PLGF testing for pregnant women with suspected preeclampsia in the middle and late stages can save costs
Duhig et al. proved in the PARROT trial that the detection of PLGF in pregnant women with suspected preeclampsia in the second and third trimester can shorten the time to diagnose preeclampsia from 4.1 days to 1.9 days, reduce the incidence of serious preeclampsia complications by 20%, and The PLGF test did not advance the delivery time . "Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis" is a cost-benefit analysis of PLGF in pregnant women with suspected pre-eclampsia in the middle and late stages of pregnancy using PARROT test data. This article is an interpretation of this document.
Address: No. 885, Chunhua Road, Haishu District, Ningbo City, Zhejiang Province
North 4th Floor, Science and Technology Building, Ningbo Haichuang Park
© 2021 Ningbo Aucheer Biotechnology Co., Ltd | 浙ICP备17032133号-2 | Powered by www.300.cn